Abp-788.mp4 <AUTHENTIC>

: Recent data from the ACE-Breast-06 study showed that ARX788 can cross the blood-brain barrier, providing a 25% objective response rate for patients with active brain metastases.

The "guide" in the video likely explains the : ABP-788.mp4

: In the ACE-Breast-02 trial , ARX788 significantly improved progression-free survival (PFS) to 11.3 months compared to 8.2 months for standard treatments. : Recent data from the ACE-Breast-06 study showed

Below is a draft guide based on the clinical profile of the ARX788 therapy, which the video likely covers. : Ongoing research is exploring its use in

: Ongoing research is exploring its use in patients with lower levels of HER2 expression, who previously had limited targeted therapy options. 2. Mechanism of Action

: Uses a highly stable oxime bond to prevent the premature release of the toxin into the bloodstream, which reduces systemic side effects.

: A potent tubulin inhibitor that kills the cancer cell once the antibody binds to the HER2 receptor and is internalized.